With $55m in fresh capital, Ulm-based NVision is expanding its quantum technology platform from MRI sensing into quantum computing for drug development. The diagnostics company Abbott is the round’s anchor investor.
Boehringer IngelheimGerman Boehringer Ingelheim is doubling down on next-generation autoimmune therapies with a deal worth up to €407.5m for a preclinical Immunitas (USA) antibody programme. The agreement highlights the growing race for selective immune-cell depletion approaches — and adds another strategic win for Novartis-, Merck-, Bayer- and Evotec-backed Immunitas.
Isomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform.
Infex Therapeutics has raised £4.3 million (€4.95 million) to advance an anti-infective pipeline led by a midphase drug candidate.
EktaH has shared early clinical trial data on its first-in-class approach to treating obesity, encouraging the biotech to aim to advance the program into Phase 2 in the first half of next year.
Cambridge-based Tolemy Bio has raised €1.4m in pre-seed financing to develop Orbit, an AI-native platform designed to help biopharma teams interpret, optimise and control cell-based therapeutic processes.
Italy’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market.
InflaRx As Amgen’s competing therapy has come under growing regulatory scrutiny, an opportunity has emerged for InflaRx N.V. to position its own oral C5aR inhibitor in the market. The Jena-based biotech company is now moving quickly to capitalise on that opening: InflaRx is refocusing its pipeline on severe renal diseases while simultaneously advancing a US$150m capital raise intended to fund development through key clinical milestones.
Scarlet Therapeutics has raised £3.2 million (€3.7 million) to take therapies based on red blood cells (RBCs) to in vivo proof of concept, building on evidence that natural and lab-grown cells have comparable half-lives.
BayerBayer AG is strengthening its ophthalmology portfolio with the acquisition of Perfuse Therapeutics for up to $2.45bn. The focus is on a Phase II candidate for glaucoma and diabetic retinopathy with potential as a disease-modifying therapy.